Galmed Pharmaceuticals Ltd. 近日宣布，其在研药物Aramchol——一种硬脂酰辅酶A去饱和酶1（SCD1）抑制剂——的新型脂质纳米颗粒（LNP）心脏靶向制剂开发取得了突破性进展。
这一创新制剂技术旨在将Aramchol特异性地递送至心脏组织，有望更精准地治疗与心脏代谢相关的疾病，同时可能减少全身性暴露带来的潜在副作用。Aramchol本身作为一种SCD1抑制剂，其作用机制是通过调节脂质代谢来发挥治疗潜力。
此次宣布的突破性进展标志着Galmed在探索Aramchol新的应用领域和递送方式上迈出了关键一步，可能为满足未竟的医疗需求开辟新的治疗途径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.